We also tested Met1 breast cancer cells, which differ from MVT-1 in their oncogenic events: Met1 cells are derived from breast tumors driven by the oncogene polyoma middle T antigen (PyMT) in a transgenic mouse model, whereas MVT-1 are from breast tumors driven by Myc and VEGF. Here, MYC is linked to breast neoplasm.